Page results
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
Penile plication (Nesbit) procedure post-operative information
-
Information on the insertion of an inflatable penile prosthesis
-
Patient Advice and Liaison Service (PALS)
-
UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Information about the Integrated Women's Service at the RLHIM patient information leaflet
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
File results
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment